Small-molecule stabilizers of hypoxia inducible factor (HIF) are being developed for the
treatment of renal anaemia. These molecules inhibit prolyl hydroxylase domain-containing …

Erythropoietin (EPO) is a glycoprotein that is mainly produced in the adult kidney, and it was
initially highlighted for its action on the hematopoietic system. Moreover, EPO is also …

The 2012 KDIGO (Kidney Disease: Improving Global Outcomes) Clinical Practice Guideline
for Anemia in Chronic Kidney Disease provides clinicians with comprehensive evidence …

Ligands selected from phage-displayed random peptide libraries tend to be directed to
biologically relevant sites on the surface of the target protein. Consequently, peptides …

Erythropoietin (EPO) is a multi-functional cytokine, which exerts erythropoietic effects but
also carries anti-apoptotic and immune-modulatory activities upon binding to two distinct …

Normocytic normochromic anemia is a common complication in chronic kidney disease and
is associated with many adverse clinical consequences. Erythropoiesis-stimulating agents …

Hemoglobin mass is a key factor for maximal exercise capacity. Some athletes apply
prohibited techniques and substances with intent to increase hemoglobin mass and physical …

Anticytokine autoantibodies are an emerging mechanism of disease in previously healthy
adults. Patients with these syndromes demonstrate a unique infectious phenotype …

Abstract Peginesatide (Omontys®; Affymax, Inc., Cupertino, CA) was voluntarily withdrawn
from the market less than a year after the product launch. Although clinical trials had …

Erythropoietin (EPO) is the main hormone regulating red blood cell (RBC) production. The
large-scale production of a recombinant human erythropoietin (rHuEPO) by biotechnological …